CCL2 and triple-A syndrome: -Inhibits the development of AAA and is associated with improvements in circulating inflammatory markers [65]-Ameliorates the development of atherosclerosis in mice with apolipoprotein E deficiency, lowers the macrophage quantity, and decreases the levels of inflammatory markers such as ICAM-1, TNF-α, and MCP-1 [76]